Bayer Contracts for New Immunoassays

The assays will be developed by Future Diagnostics, b.v. (Wijchen, The Netherlands).

In the agreement's first phase, four immunoassays are to be developed. Two of these, a sex-hormone-binding globulin (SHBG) assay and a dehydroepiandrosterone sulfate (DHEA-s) assay will be added to Bayer's fertility panel. The other two assays to be developed are an unconjugated estrial (uE3) assay that monitors fetal maturity and well-being, and a D-dimer assay for the diagnosis of deep vein thrombosis or pulmonary embolism.

These assays will allow Bayer to expand its immunoassay menu on the Advia Centaur family of instruments. "In response to market drivers and customer requests, there is a need for labs to consolidate their laboratory instruments,” said Tom Warekois, senior vice president of global strategic marketing for Bayer's Diagnostic Division. "Working in parallel with Future Diagnostics, we will expedite new assays to the market to meet lab
needs.”

"By providing professional experienced immunoassay contract research and development, Future Diagnostics is well suited to work with Bayer to expand their immunoassay capabilities and accelerate the release of the assays to the market,” said Frans Rosmalen, president and CEO of Future Diagnostics.





Related Links:
Bayer Diagnostics Division
Future Diagnostics